|
1
|
Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
|
Anticancer Res
|
2008
|
1.06
|
|
2
|
Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells.
|
Cancer Sci
|
2009
|
1.01
|
|
3
|
Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer.
|
World J Gastroenterol
|
2006
|
0.95
|
|
4
|
LIM only 4 is overexpressed in late stage pancreas cancer.
|
Mol Cancer
|
2008
|
0.94
|
|
5
|
S100P is an early developmental marker of pancreatic carcinogenesis.
|
Clin Cancer Res
|
2006
|
0.92
|
|
6
|
Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer.
|
Anticancer Res
|
2007
|
0.90
|
|
7
|
Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
|
Cancer Lett
|
2010
|
0.84
|
|
8
|
Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.
|
Anticancer Res
|
2011
|
0.81
|
|
9
|
Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway.
|
Cancer Sci
|
2010
|
0.81
|
|
10
|
Quantitative analysis of hTERT mRNA levels in cells microdissected from cytological specimens.
|
Cancer Sci
|
2008
|
0.81
|
|
11
|
Midkine mRNA is overexpressed in pancreatic cancer.
|
Dig Dis Sci
|
2008
|
0.81
|